MedTrace Logo

Metformin for the Prevention of CRA Recurrence

NCT04885426 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 414

Last updated 2021-05-13

No results posted yet for this study

Summary

Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.

Conditions

  • Colorectal Adenoma
  • Metformin
  • Chemoprevention

Interventions

DRUG

low-dose metformin

Metformin Pill 250mg/day

DRUG

high-dose metformin

Metformin Pill 500mg/day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Jing-yuan Fang, MD, Ph. D

    lead OTHER

Principal Investigators

  • Jing-Yuan Fang, Professor · Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885426 on ClinicalTrials.gov